Latest Tax Incentives News

Everest Metals Corporation has announced the issuance of $1.17 million in Junior Minerals Exploration Incentive tax credits to eligible shareholders following successful capital raisings in 2024-25. This move highlights the company’s ongoing commitment to exploration and shareholder value.

Opthea Limited has announced a strategic pivot to develop OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women, aiming for ASX reinstatement in 2026. The company leverages strong intellectual property and cash reserves to pursue orphan drug designation and clinical development.

Recce Pharmaceuticals has won a significant Australian Government R&D tax incentive, unlocking up to A$85 million for its synthetic anti-infective programs worldwide, including a pivotal Phase 3 clinical trial.

Galan Lithium advances its Hombre Muerto West project with key infrastructure in transit and construction progressing ahead of schedule, targeting lithium chloride production in the first half of 2026.

Pilot Energy has secured a $1.52 million financing facility to fast-track its FY2025 R&D Tax Incentive refund, supporting its clean energy and gas exploration projects.

Pilot Energy has sold its option to lease a solar development site to Strike Energy, a move prompted by recent government policy changes excluding blue hydrogen from key tax incentives.

Algorae Pharmaceuticals has secured a $384,466 cash refund from the Australian Taxation Office, reinforcing its financial position to advance AI-driven drug discovery programs.

Livium Ltd has secured a A$663,000 R&D tax rebate for its subsidiary VSPC, pushing total FY25 rebates to A$1.4 million and reinforcing its push into advanced battery materials and recycling.

Terragen Holdings has received nearly $1 million in R&D tax incentives, reinforcing its cash position and fueling ongoing development of its innovative agricultural biotech products.

InhaleRx has boosted its funding facility by $12.6 million to accelerate clinical trials of SRX-25, a novel oral treatment for Treatment-Resistant Depression. This brings total available capital to $52.3 million, positioning the company for pivotal Phase III studies.

FireFly Metals has raised approximately A$139 million to accelerate exploration and development at its Green Bay Copper-Gold Project in Canada, setting the stage for a major resource expansion and a Final Investment Decision in 2026.

AdAlta Limited has received a $0.78 million Research and Development Tax Incentive refund for FY2025, using part of it to repay a Radium Capital loan and strengthening its cash position as it nears a key licensing milestone.